Biotech Bio Series #5: Stay Clear Of Biogen  Seeking Alpha

Biogen’s largest revenue driver, its multiple sclerosis franchise, has seen stagnant growth and has a bleak future ahead. Its new drug Spinraza is growing stron.

X